For FLNA linkages to all three receptors in synaptosomes from AD versus age-, gender- and postmortem-interval-matched healthy control brain tissue, two-way ANOVAs showed highly significant main effects of diagnosis (CXCR4: F = 22.30, p < 0.0001; CD4: F = 188.52, p < 0.0001; CCR5: F = 179.43, p < 0.0001) and treatment (CXCR4: F = 44.39, p < 0.0001; CD4: F = 140.48, p < 0.0001; CCR5: F = 35.78, p < 0.0001) and a diagnosis–treatment interaction (CXCR4: F = 22.29, p < 0.0001; CD4: F = 109.68, p < 0.0001; CCR5: F = 79.78, p < 0.0001). This evidence concerns the gene CCR5 and Alzheimer disease.